Navigation Links
Dominion Diagnostics Continues To Lead Through 'On Demand' Laboratory Science
Date:10/7/2009

NORTH KINGSTOWN, R.I., Oct. 7 /PRNewswire/ -- Only a short time after introducing its newly developed and validated tapentadol assay, Dominion Diagnostics (Dominion) is pleased to announce an important enhancement to another clinical laboratory test.

For its pain management clients, Dominion has refined its laboratory testing procedure for the opioid medication fentanyl. Dominion has now lowered the limit of quantification (LOQ) for the primary metabolite, norfentanyl, to 1 ng/mL. Like many of the other assays Dominion provides for clients, this testing procedure is performed by ultra performance liquid chromatography tandem mass spectrometry (UPLC®-MS/MS).

The synthetic opioid fentanyl undergoes extensive metabolism, with only 0.4-6.0% eliminated in the urine as unchanged drug and as much as 55% excreted as the primary metabolite, norfentanyl. Metabolism and excretion studies have also shown that norfentanyl can be detected in the urine of patients approximately three times longer than that of the parent compound(1). As a result of the increased availability of norfentanyl in the urine, as well as the expanded window of detection, Dominion has lowered the LOQ of norfentanyl, thereby increasing the overall analytical sensitivity of the testing procedure.

"As part of Dominion's quality assurance program, our laboratory managers and directors regularly review each assay's performance specifications and make modifications as needed," said Assistant Laboratory Director, Charlene Johnson, Ph.D. "Our goal is to provide clients with scientifically sound and accurate results using the most reliable and up-to-date methods."

The demand for clinical monitoring using highly sensitive and specific clinical laboratory procedures continues to grow, especially as the industry begins to face the FDA's new Risk Evaluation and Mitigation Strategy (REMS). Dominion continues to lead the industry in its development of highly relevant UPLC-MS/MS procedures that assist practitioners in scientifically accurate patient adherence monitoring and chronic opioid pharmacotherapy.

Source:

(1) Baselt, R. Disposition of Toxic Drugs and Chemicals in Man, 7th edition, 2004.

UPLC is a trademark of Waters Corporation.

ABOUT DOMINION DIAGNOSTICS

Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Pain Medicine, Primary Care, Addiction Medicine, Behavioral Health, Psychiatry and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.

    Contact:
    Julie Lenahan
    Director of Marketing
    Dominion Diagnostics
    (401) 667-0876
    jlenahan@dominiondiagnostics.com

SOURCE Dominion Diagnostics


'/>"/>
SOURCE Dominion Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
2. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
3. Strategic Diagnostics Updates Roth Conference Presentation Time
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
8. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):